Granulocyte colony-stimulating factor (GCSF) is a glycoprotein that contains growth factors and aids in endometrial tissue development. The patient must have a receptive endometrium, as well as several other characteristics, for IVF treatment to be successful. Despite the multiple treatments available today for endometrial growth, no optimum medicine or strategy for enhancing endometrial density is available.
G-CSF (granulocyte colony-stimulating factor) is a glycoprotein that belongs to the colony-stimulating factor family. It aids in the formation of granulocyte colonies. Many cells, including endothelial monocytes and endometrial cells, produce G-CSF, which is an amino acid polypeptide. Endometrial decidualization, trophoblast development, and placental metabolism are all aided by G-CSF. G-CSF is involved in stem cell mobilization, migration, and differentiation. It also promotes endometrial regeneration by increasing angiogenesis and decreasing endometrial cell apoptosis.
Before the embryo transfer, GCSF is commonly injected intrauterine or administered subcutaneously, and it has been shown to help with implantation failures caused by thin endometrium. Experts usually administer one or two intrauterine G CSF applications. If the endometrium remains resistant, intrauterine platelet-rich plasma, or PRP, may be used. Thirty milliliters of blood are to be extracted from individuals in this procedure. FDA-approved equipment is used to process this blood. About 3-4 ml of PRP is to be collected from this. PRP is injected into the uterine cavity in a dose of 0.5 mL.
Injection GCSF is more effective than PRP in boosting endometrial density in patients with minimal endometrium. In a study, patients who received injection GCSF had a slightly higher clinical pregnancy rate (44%) than those who received intrauterine PRP, which had a rate of 28 percent. All of the other variables were similar.
In comparison to intrauterine PRP infusion, injection GCSF is more successful in the treatment of thin endometrial patients. Despite the fact that the clinical and chemical pregnancy rates were comparable, the injection GCSF group had a larger percentage of clinically pregnant women. For thin endometrium, intrauterine PRP can be a useful alternative.